{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-126382","form_type":"8-K","ticker":"STRO","cik":"0001382101","company_name":"SUTRO BIOPHARMA, INC.","filed_at":"2024-11-13T23:59:59+00:00","discovered_at":"2026-05-14T18:03:08.301934+00:00","generated_at":"2026-05-30T00:50:36.601094+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"medium","headline":"Sutro Biopharma Q3 2024: revenue $8.5M, cash $388.3M, luvelta registrational trial underway","bullets":["Cash, equivalents, and marketable securities $388.3M as of September 30, 2024.","Revenue $8.5M for Q3 2024, down from $16.9M in Q3 2023 (49.7% decrease).","Total operating expenses $76.4M, up from $60.9M in Q3 2023; R&D $62.1M, G&A $14.3M.","Realized gain of $32.1M from sale of Vaxcyte shares; no remaining Vaxcyte holdings.","Initiated registrational trial for luvelta in pediatric leukemia; IND for STRO-004 expected H2 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-126382","json":"https://secwatch.observer/filing/0000950170-24-126382.json","markdown":"https://secwatch.observer/filing/0000950170-24-126382.md","text":"https://secwatch.observer/filing/0000950170-24-126382.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1382101/000095017024126382/0000950170-24-126382-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1382101/000095017024126382/stro-20241113.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T00:50:36.601094+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}